The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | NGS: changes in CLL management
Richard Rosenquist Brandell, MD, of Karolinska Institute, Solna, Stockholm, discusses how the management of chronic lymphocytic leukemia (CLL) has changed since the advent of next-generation techniques as well as gene panel assays currently used for CLL prognosis and resistance assesment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
